BR112018076015A8 - Formulações imunogênicas compreendendo adjuvantes de polímero do ácido poliacrílico linear ou ramificado . - Google Patents

Formulações imunogênicas compreendendo adjuvantes de polímero do ácido poliacrílico linear ou ramificado .

Info

Publication number
BR112018076015A8
BR112018076015A8 BR112018076015A BR112018076015A BR112018076015A8 BR 112018076015 A8 BR112018076015 A8 BR 112018076015A8 BR 112018076015 A BR112018076015 A BR 112018076015A BR 112018076015 A BR112018076015 A BR 112018076015A BR 112018076015 A8 BR112018076015 A8 BR 112018076015A8
Authority
BR
Brazil
Prior art keywords
polyacrylic acid
acid polymer
including linear
formulations including
immunogenic formulations
Prior art date
Application number
BR112018076015A
Other languages
English (en)
Other versions
BR112018076015A2 (pt
Inventor
Rigaut Gullaume
Guy André Lucien Parisot Alexis
De Luca Karelle
Michele Pierrette Andreoni Christine
REMOLUE Lydie
GARINOT Marie
Cotte Jean-Francois
Probeck-Quellect Patricia
Haensler Jean
Chambon Véronique
TALAGA Philippe
Original Assignee
Sanofi Pasteur
Merial Inc
Boehringer Ingelheim Animal Health Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur, Merial Inc, Boehringer Ingelheim Animal Health Usa Inc filed Critical Sanofi Pasteur
Publication of BR112018076015A2 publication Critical patent/BR112018076015A2/pt
Publication of BR112018076015A8 publication Critical patent/BR112018076015A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F6/00—Post-polymerisation treatments
    • C08F6/001—Removal of residual monomers by physical means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F120/04—Acids; Metal salts or ammonium salts thereof
    • C08F120/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A presente invenção fornece novas formulações imunológicas e vacinas compreendendo um adjuvante de polímero de ácido poliacrílico não reticulado, recentemente aplicado. Os adjuvantes podem ser combinados com uma grande variedade de imunógenos para produzir vacinas que são seguras e eficazes quando administradas a uma vasta gama de animais alvo. Os imunógenos podem incluir, mas não estão limitados a: patógenos inativados, patógenos atenuados, subunidades, vetores de expressão recombinantes, plasmídeos ou combinações dos mesmos. Os animais podem incluir, mas não estão limitados a: humanos, murinos, caninos, felinos, equinos, suínos, ovinos, caprinos e bovinos.
BR112018076015A 2016-06-17 2017-06-15 Formulações imunogênicas compreendendo adjuvantes de polímero do ácido poliacrílico linear ou ramificado . BR112018076015A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351492P 2016-06-17 2016-06-17
US62/351,492 2016-06-17
US2017218819 2017-12-21

Publications (2)

Publication Number Publication Date
BR112018076015A2 BR112018076015A2 (pt) 2019-03-26
BR112018076015A8 true BR112018076015A8 (pt) 2022-06-28

Family

ID=59295306

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018076015A BR112018076015A8 (pt) 2016-06-17 2017-06-15 Formulações imunogênicas compreendendo adjuvantes de polímero do ácido poliacrílico linear ou ramificado .

Country Status (10)

Country Link
US (1) US11554170B2 (pt)
EP (1) EP3471760A1 (pt)
JP (1) JP7018941B2 (pt)
KR (1) KR20190044052A (pt)
CN (1) CN109475615B (pt)
AU (1) AU2017286727B2 (pt)
BR (1) BR112018076015A8 (pt)
CA (1) CA3027877A1 (pt)
MX (1) MX2018015787A (pt)
WO (1) WO2017218819A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018331874B2 (en) * 2017-09-13 2022-06-02 Sanofi Pasteur Human cytomegalovirus immunogenic composition
WO2019195314A2 (en) 2018-04-03 2019-10-10 Sanofi Antigenic epstein barr virus polypeptides
CA3095175A1 (en) 2018-04-03 2019-10-10 Sanofi Antigenic respiratory syncytial virus polypeptides
JP2021519596A (ja) 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ フェリチンタンパク質
WO2019195284A1 (en) 2018-04-03 2019-10-10 Sanofi Antigenic influenza-ferritin polypeptides
KR20210018205A (ko) 2018-04-03 2021-02-17 사노피 항원성 OspA 폴리펩타이드
CN109134724A (zh) * 2018-07-24 2019-01-04 石家庄哈顿生物技术有限公司 一种动物疫苗用聚丙烯酸类聚合物佐剂的研制方法
BR112021013241A2 (pt) * 2019-01-04 2021-09-14 Boehringer Ingelheim Animal Health USA Inc. Cepas atenuadas de bordetella bronchiseptica, vacinas orais contendo as cepas atenuadas e métodos de preparação e uso das mesmas
JP2022525431A (ja) 2019-04-02 2022-05-13 サノフイ 抗原性多量体呼吸器合胞体ウイルスポリペプチド
CN113444743A (zh) * 2021-06-22 2021-09-28 贵州大学 含佐剂基因的羊支原体肺炎二价核酸疫苗的构建方法
WO2023120535A1 (ja) * 2021-12-20 2023-06-29 東興薬品工業株式会社 ポリアクリル酸系ポリマーを含有するワクチンアジュバント剤およびその使用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3790665A (en) 1968-02-23 1974-02-05 Haver Lockhart Labor Inc Injectable adjuvant,method of preparing same and compositions including such adjuvant
US3919411A (en) 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
NZ215069A (en) * 1985-03-01 1988-06-30 Reckitt & Colmann Prod Ltd Pharmaceutical composition with histamine h 2 -receptor antagonist
DE68929478T2 (de) 1988-01-29 2004-04-29 Aventis Pasteur Rekombinante CMV-Neutralisierungsproteine
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
US5846805A (en) 1991-08-26 1998-12-08 Boehringer Ingelheim Animal Health, Inc. Culture of swine infertility and respiratory syndrome virus in simian cells
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
DK0683816T3 (da) 1993-02-08 2001-01-08 Bayer Ag Fremgangsmåde til dyrkning af porcinreproduktions- og respirationssygdom-virus og dets anvendelse i vacciner
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
BE1008977A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5866401A (en) 1996-03-01 1999-02-02 Schering Corporation Porcine reproductive and respiratory syndrome vaccine
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
TWI224107B (en) 1998-10-22 2004-11-21 Pfizer Prod Inc Novel proteins from actinobacillus pleuropneumoniae
JP2006528647A (ja) 2003-07-24 2006-12-21 メリアル リミテッド 新規ワクチン製剤
GB0400264D0 (en) 2004-01-07 2004-02-11 Polytherics Ltd Complexes
US7425336B2 (en) 2005-08-25 2008-09-16 Mevial Limited Canine influenza vaccines
GB0805356D0 (en) 2008-03-25 2008-04-30 Isis Innovation Vaccine adjuvant composition
CA2791853C (en) 2010-02-12 2018-03-06 Rhodia Operations Rheology modifier compositions and methods of use
CA3170184A1 (en) 2012-03-12 2013-09-19 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions

Also Published As

Publication number Publication date
CN109475615B (zh) 2023-04-07
JP7018941B2 (ja) 2022-02-14
WO2017218819A1 (en) 2017-12-21
JP2019524873A (ja) 2019-09-05
AU2017286727B2 (en) 2024-02-08
BR112018076015A2 (pt) 2019-03-26
MX2018015787A (es) 2019-04-22
US11554170B2 (en) 2023-01-17
KR20190044052A (ko) 2019-04-29
CA3027877A1 (en) 2017-12-21
EP3471760A1 (en) 2019-04-24
CN109475615A (zh) 2019-03-15
US20170360923A1 (en) 2017-12-21
AU2017286727A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
BR112018076015A8 (pt) Formulações imunogênicas compreendendo adjuvantes de polímero do ácido poliacrílico linear ou ramificado .
BR112017005833A2 (pt) vacinas recombinantes fmdv e seus usos
CY1124288T1 (el) Cmv εμβολια
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
CL2019003805A1 (es) Composiciones inmunógenas de senecavirus a y métodos de éstas.
BR112012023852A2 (pt) vacinas recombinantes do vírus da língua azul e usos das mesmas
BR112018068719A2 (pt) métodos para produzir uma resposta imunogênica em um animal aquático e composição farmacêutica
BR112017004032A2 (pt) formulação tópica
BR112016028066A2 (pt) composição de vacina; idessuis; ridessuis; anticorpo; composição parenteral; uso de uma proteína idessuis ou ridessuis; e célula hospedeira
EA201791910A1 (ru) Инъецируемые препараты длительного действия, содержащие изоксазолиновое действующее вещество, способы и применение
BR112016006326A2 (pt) formulação seca de uma vacina, uso de uma formulação seca, método para fabricação de uma formulação seca, e, vacina
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
CY1124218T1 (el) Ανασυνδυασμενοι αδενοϊικοi φορεις εμβολιων fmdv και χρησεις αυτων
EA201990718A1 (ru) Векторы аденовируса собачьих
BR112018003967A2 (pt) tratamento de hipersensibilidade à picada de inseto
BR112018074483A2 (pt) proteínas f do rsv pré-fusão estabilizadas
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
BR112018070634A2 (pt) vacina universal para doenças virais
BR112018071121A2 (pt) dispositivo de injeção energizados para fornecer formulações de múltiplos líquidos, incluindo vacinas
RU2018127403A (ru) Поливалентная вакцина против hyo и ее применение
BR112017027895A2 (pt) vetores virais recombinantes contendo proteínas menores de prrsv e métodos de fabricação e utilização destes
BR112014020025A8 (pt) Vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
US20170021009A1 (en) Heat Inactivated Poxvirus Improves Vaccination Results
BR112018010494A8 (pt) proteínas de fusão fmdv e e2 e seus usos
BR112019008720A2 (pt) polinucleotídeo isolado, polinucleotídeo de cdna, polinucleotídeo infeccioso, composição, composição farmacêutica, vetor de pestivírus porcino, pestivírus quimérico, vacina para animais, kit, métodos para proteger um leitão contra uma doença associada com pestivírus, detectar pestivírus, detectar antígeno de pestivírus, preparar uma vacina e controlar uma infecção com um pestivírus em animais, e, ensaio diagnóstico

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25G Requested change of headquarter approved

Owner name: SANOFI PASTEUR (FR) ; MERIAL, INC. (US)

B25A Requested transfer of rights approved

Owner name: SANOFI PASTEUR (FR) ; BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]